Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 5/20 | 0.56 |
| ▸ | RAB9A | P51151 | 5/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.56 |
| ▸ | CTSK | P43235 | 2/20 | 0.52 |
| ▸ | CTSS | P25774 | 1/20 | 0.52 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.51 |
| ▸ | BRD4 | O60885 | 1/20 | 0.51 |
| ▸ | ADAM17 | P78536 | 3/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.48 |
| ▸ | NQO2 | P16083 | 1/20 | 0.47 |
| ▸ | MALT1 | Q9UDY8 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | CA12 | O43570 | 1/20 | 0.45 |
| ▸ | CA1 | P00915 | 1/20 | 0.45 |
| ▸ | CA2 | P00918 | 1/20 | 0.45 |
| ▸ | CA9 | Q16790 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14610193 | 0.86 | CTSK (0.53) | SMN1; SMN2CTSKCTSSALDH1A1MAPT | |
| SCHEMBL1163822 | 0.85 | CTSK (0.60) | RAB9ASMN1; SMN2CTSKCTSSALDH1A1 | |
| SCHEMBL23012627 | 0.85 | LMNA (0.56) | NPC1RAB9ASMN1; SMN2CTSKCTSS | |
| SCHEMBL21751228 | 0.83 | DPP4 (0.46) | NPC1RAB9ASMN1; SMN2CTSKCTSS | |
| SCHEMBL28820411 | 0.83 | POLB (0.56) | NPC1RAB9ASMN1; SMN2CTSKCTSS | |
| SCHEMBL31396774 | 0.83 | RAB9A (0.62) | NPC1RAB9ASMN1; SMN2TAAR1BRD4 | |
| SCHEMBL14610192 | 0.82 | CTSK (0.53) | SMN1; SMN2CTSKCTSSALDH1A1MAPT | |
| SCHEMBL22734664 | 0.82 | KMT2A (0.50) | ALDH1A1HPGDHTT | |
| SCHEMBL12394933 | 0.81 | KDM4E (0.60) | NPC1RAB9ASMN1; SMN2ALDH1A1MAPT | |
| SCHEMBL25003323 | 0.81 | MALT1 (0.51) | CTSKCTSSBRD4ALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4731216-A1 | HETEROARYL-AMINE COMPOUNDS AND USE THEREOF AS HDAC6 INHIBITORS | Augustine Therapeutics (BE) | 2026-04-29 | — | — | EP | disclosed |
| US-12435100-B2 | Perovskite solar cells | PURDUE RESEARCH FOUNDATION (US) | 2025-10-07 | — | — | US | disclosed |
| US-12421222-B2 | Substituted quinazolines as HDAC6 inhibitors | AUGUSTINE THERAPEUTICS (BE) | 2025-09-23 | — | — | US | disclosed |
| US-20250145604-A1 | COMPOUNDS AND USE THEREOF AS HDAC6 INHIBITORS | AUGUSTINE THERAPEUTICS (BE) | 2025-05-08 | — | — | US | disclosed |
| US-20250051319-A1 | COMPOUNDS AND USE THEREOF AS HDAC6 INHIBITORS | AUGUSTINE THERAPEUTICS (BE) | 2025-02-13 | — | — | US | disclosed |
| WO-2024261329-A1 | HETEROARYL-AMINE COMPOUNDS AND USE THEREOF AS HDAC6 INHIBITORS | AUGUSTINE THERAPEUTICS (BE) | 2024-12-26 | — | — | WO | disclosed |
| EP-4452265-A2 | COMPOUNDS AND USE THEREOF AS HDAC6 INHIBITORS | Augustine Therapeutics (BE) | 2024-10-30 | — | — | EP | disclosed |
| US-11800784-B2 | Two-dimensional halide perovskite materials | PURDUE RESEARCH FOUNDATION (US) | 2023-10-24 | — | — | US | disclosed |
| US-11800784-B2 | Two-dimensional halide perovskite materials | PURDUE RESEARCH FOUNDATION (US) | 2023-10-24 | — | — | US | disclosed |
| US-11800784-B2 | Two-dimensional halide perovskite materials | PURDUE RESEARCH FOUNDATION (US) | 2023-10-24 | — | — | US | disclosed |
| US-10618889-B2 | Thiophene monoamine based organic-inorganic hybrid perovskites | PURDUE RESEARCH FOUNDATION (US) | 2020-04-14 | — | — | US | disclosed |
| US-20200062740-A1 | THIOPHENE MONOAMINE BASED ORGANIC-INORGANIC HYBRID PEROVSKITES | PURDUE RESEARCH FOUNDATION (US) | 2020-02-27 | — | — | US | disclosed |
| US-20200062740-A1 | THIOPHENE MONOAMINE BASED ORGANIC-INORGANIC HYBRID PEROVSKITES | PURDUE RESEARCH FOUNDATION (US) | 2020-02-27 | — | — | US | disclosed |
| CN-108290878-A | NOVEL FERROPORTIN INHIBITORS | 威佛（国际）股份公司 | 2018-07-17 | — | — | CN | disclosed |
| CN-102056894-A | Homocysteine synthase inhibitor | MITSUBISHI TANABE PHARMA CORP | 2011-05-11 | — | — | CN | disclosed |
| EP-1503761-A1 | SUBSTITUTED PIPERAZINES AS MELANOCORTIN RECEPTOR LIGANDS | Neurocrine Biosciences, Inc. (US) | 2005-02-09 | — | — | EP | disclosed |
| US-6723716-B1 | BACTERICIDE FOR STAPHYLOCOCCUS | ESSENTIAL THERAPEUTICS, INC. | 2004-04-20 | — | — | US | disclosed |
| WO-2003094918-A1 | SUBSTITUTED PIPERAZINE AS MELANOCORTIN RECEPTORS LIGANDS | NEUROCRINE BIOSCIENCES, INC. (US) | 2003-11-20 | — | — | WO | disclosed |
| EP-1222194-A1 | 7-ACYLAMINO-3-HETEROARYLTHIO-3-CEPHEM CARBOXYLIC ACID ANTIBIOTICS AND PRODRUGS THEREOF | Essential Therapeutics, Inc. (US) | 2002-07-17 | — | — | EP | disclosed |
| WO-2001021623-A1 | 7-ACYLAMINO-3-HETEROARYLTHIO-3-CEPHEM CARBOXYLIC ACID ANTIBIOTICS AND PRODRUGS THEREOF | ESSENTIAL THERAPEUTICS, INC. (US) | 2001-03-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250051319-A1 | COMPOUNDS AND USE THEREOF AS HDAC6 INHIBITORS | HDAC6, HDAC9, HDAC1 | NPC1 620/4885RAB9A 75/4885SMN1; SMN2 60/4885 |
| US-10618889-B2 | Thiophene monoamine based organic-inorganic hybrid perovskites | COMT, TYR, SLC6A3 | NPC1 3119/4885RAB9A 1561/4885SMN1; SMN2 3017/4885 |
| US-20250145604-A1 | COMPOUNDS AND USE THEREOF AS HDAC6 INHIBITORS | HDAC6, HDAC9, HDAC1 | NPC1 620/4885RAB9A 75/4885SMN1; SMN2 60/4885 |
| US-12435100-B2 | Perovskite solar cells | BCL3, MCL1, ANXA3 | NPC1 2585/4885RAB9A 602/4885SMN1; SMN2 2278/4885 |
| US-12421222-B2 | Substituted quinazolines as HDAC6 inhibitors | HDAC6, HDAC9, HDAC1 | NPC1 916/4885RAB9A 48/4885SMN1; SMN2 92/4885 |
| US-11800784-B2 | Two-dimensional halide perovskite materials | EYA2, BRAP, EYA3 | NPC1 2261/4885RAB9A 330/4885SMN1; SMN2 2196/4885 |
| US-20200062740-A1 | THIOPHENE MONOAMINE BASED ORGANIC-INORGANIC HYBRID PEROVSKITES | COMT, TYR, SLC6A3 | NPC1 3119/4885RAB9A 1561/4885SMN1; SMN2 3017/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.